acid maltase

acid maltase

/ac·id mal·tase/ (mawl´tās) a hydrolase that catalyzes the degradation of glycogen to glucose in the lysosomes; deficiency of enzyme activity results in glycogen storage disease, type II.

Patient discussion about acid maltase

Q. help with tingling in the hands amd numness

A. I have experienced the same conditions in the past on numerous occasions. The malady, more than likely, is Carpal Tunnel Syndrome. You should consult a neurologist for a diagnosis.

More discussions about acid maltase
References in periodicals archive ?
It is known by several names: acid maltase deficiency; glycogen storage disease type II; and glycogenosis type II.
One of the main attractions will be keynote speaker John Crowley, best known as the inspiration for the 2010 film Extraordinary Measures, which details his efforts to find a cure for Pompe's disease (or acid maltase deficiency) to save his two youngest children who suffer from it.
Beaudette went to UMass Memorial Medical Center in Worcester, where it was determined she had contracted late-onset acid maltase deficiency, more commonly known as Pompe disease.
Pompe disease, first identified in 1932 by Dutch pathologist Johann Pompe, is a condition in which a person is born with an extreme shortage of the acid maltase enzyme.
Metabolic Diseases of Muscles These are caused by inherited chemical deficiencies of a specific enzyme, such as phosphorylase (McArdle's disease), acid maltase (Pompe's disease) or carnitine palmitoyl transferase.
Urine samples from adult Pompe patients (n = 5) were obtained through the Acid Maltase Deficiency Association (Australia).
Pompe disease, also known as glycogen storage disease type II or acid maltase deficiency, is a relatively rare lysosomal storage disorder caused by an inherited mutation in the lysosomal enzyme alpha-glucosidase (GAA).
In healthy individuals, acid maltase breaks down sugars that are stored in the body's muscle cells.
House, chairman of the International Pompe Association and president of the Acid Maltase Deficiency Association (AMDA), a Pompe patient association in the United States.
Currently, the treatment being studied is acid maltase enzyme replacement; gene therapy is also being evaluated for use in the future.
Many health conditions such as kidney failure, post-surgical overload and metabolic diseases such as glucose intolerance, hyperglycemia and acid maltase can cause fluid-overload, however congestive heart failure (CHF) is the leading cause.
Pompe's disease, also called acid maltase deficiency or glycogen storage disorder type II, is caused by a complete or partial deficiency of the enzyme human alpha-glucosidase, and affects an estimated 5,000 - 10,000 people in the Western world.